YOLFTbeta
00

Beijing New Oriental Star Petrochemical Engineering Co Ltd

002755 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

12.21CNY-0.38 (-3.02%)

Price History

Full chart

Market Stats

Previous Close12.59
Open12.56
Day Range12.16 – 12.64
52-Week Range11.02 – 20.57
Volume5.27M
Market Cap12.58B
P/E (TTM)64.52
Forward P/E0.00
EPS0.21
Dividend Yield0.89%
Beta0.08
50-Day Avg12.61
200-Day Avg14.82

About

Beijing Aosaikang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of active pharmaceutical ingredients and formulations in China. It also offers digestive health products, which include pump inhibitors suitable for various digestive tract-related diseases, such as peptic ulcers, reflux esophagitis, and upper gastrointestinal bleeding; and anti-tumor products, including the treatment of non-small cell lung cancer, colorectal cancer, and breast cancer, encompassing targeted therapy, chemotherapy, endocrine therapy, and adjuvant medications. In addition, the company provides anti-infective products comprising a product defense line against bacterial and invasive fungal infections; and the chronic disease field focusing on chronic diseases requiring long-term management consisting of diabetes, osteoarthritis, thrombocytopenia, and iron overload. Beijing Aosaikang Pharmaceutical Co., Ltd. was founded in 1996 and is based in Nanjing, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Jingfei Ma
  • Employees799
  • HeadquartersJiangning Science Park, Nanjing, China, 211112, China
  • Websitehttps://www.ask-pharm.com

Leadership

  • Mr. Jingfei MaGM & Director · b. 1988
  • Mr. Tao HanCFO & Head of Accounting Department · b. 1982
  • Mr. Xiangfeng ChenDeputy GM & Non-Independent Director · b. 1970

Financials

Income Statement

Currency: CNY2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-529.17M2.04B488.92M470.87M3.01B3.09B3.40B3.93B4.52B3.78B3.11B1.87B1.44B1.78B1.78B
Growth (%)--+285.68%-76.04%-3.69%+539.49%+2.69%+10.11%+15.48%+14.92%-16.29%-17.87%-39.72%-22.92%+23.15%+0.08%
Cost of Revenue-393.90M146.58M363.50M343.93M183.72M206.88M241.89M277.77M336.21M311.44M277.05M245.70M277.51M333.53M351.87M
Gross Profit-135.27M1.89B136.92M126.94M2.83B2.89B3.16B3.65B4.18B3.47B2.83B1.63B1.17B1.44B1.43B
Gross Margin-25.56%92.82%28.00%26.96%93.90%93.31%92.90%92.94%92.56%91.77%91.08%86.88%80.77%81.24%80.22%
Operating Expense-78.02M1.82B71.95M82.31M2.25B2.16B2.47B2.91B3.31B2.68B2.43B1.89B1.39B1.29B1.19B
Operating Income-57.25M70.58M64.97M44.64M580.22M722.27M690.16M744.48M872.00M790.30M402.51M-260.02M-219.88M156.94M236.77M
Operating Margin-10.82%3.46%13.29%9.48%19.27%23.36%20.27%18.93%19.30%20.89%12.96%-13.89%-15.23%8.83%13.31%
EBITDA-64.62M304.53M67.57M46.85M598.02M735.87M727.90M798.19M930.72M825.17M401.33M-224.03M-208.79M169.84M383.21M
EBITDA Margin-12.21%14.92%13.82%9.95%19.86%23.80%21.38%20.30%20.60%21.81%12.92%-11.96%-14.46%9.55%21.54%
Net Income-49.14M59.95M55.52M37.50M509.01M629.98M607.54M670.07M780.96M721.63M379.91M-225.83M-148.53M160.29M236.60M
Net Income Margin-9.29%2.94%11.36%7.96%16.90%20.37%17.84%17.04%17.28%19.08%12.23%-12.06%-10.29%9.02%13.30%
R&D--99.64M19.45M13.29M163.34M178.45M226.93M290.27M310.10M255.89M324.45M588.84M472.01M186.22M158.61M
R&D as % of Total Revenue--4.88%3.98%2.82%5.42%5.77%6.66%7.38%6.86%6.76%10.44%31.45%32.70%10.48%8.92%
Interest Expense0087.58K--81.82K53.89K1.13M782.11K356.07K3.23M4.28M3.46M3.08M2.97M895.88K
Interest Expense % of Total Revenue-0.00%0.00%--0.00%0.00%0.03%0.02%0.01%0.09%0.14%0.18%0.21%0.17%0.05%

Balance Sheet

Currency: CNY2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-446.22M604.82M581.97M582.66M716.42M690.57M866.57M2.96B3.69B3.81B3.72B3.41B3.52B4.05B4.52B
Total Liabilities-231.39M341.43M274.46M249.04M208.08M181.17M281.55M1.12B1.18B774.89M497.24M401.03M513.20M905.39M1.24B
Total Equity273.22M214.83M263.39M307.51M333.61M508.35M509.40M519.18M1.84B2.51B3.03B3.22B2.96B2.90B3.06B3.22B
Cash-87.35M176.66M150.33M100.87M254.18M270.78M189.57M1.08B1.19B1.37B1.17B772.71M1.05B1.41B1.42B
Total Debt-----55.00M3.00M10.92M4.09M554.49K20.01M14.13M57.41M120.77M68.62M-
Net Debt--87.35M-176.66M-150.33M-100.87M-199.18M-267.78M-178.65M-1.08B-1.19B-1.35B-1.15B-715.31M-923.25M-1.34B-

Cash Flow

Currency: CNY2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow55.28M33.29M106.47M-13.35M-35.30M-802.68K16.73M-50.30M497.16M534.62M580.38M567.71M-52.81M-26.57M411.36M651.64M
Investing Cash Flow--6.35M-4.59M-2.80M-1.55M-1.76M-4.08M-39.25M-141.77M-294.38M-215.74M-563.02M-438.92M11.56M-173.24M-
Financing Cash Flow--7.60M-11.40M-11.34M-11.46M155.87M-3.55M5.07M-15.45M-124.72M-182.82M-209.74M75.91M291.17M43.11M-
Capital Expenditure40.19M6.57M4.60M2.81M1.87M2.29M4.10M3.87M95.84M169.02M199.68M133.76M150.45M129.32M230.42M143.58M
Free Cash Flow-26.72M101.87M-16.16M-37.17M-3.09M12.63M-54.17M401.32M365.60M380.70M433.95M-203.27M-155.89M180.94M508.07M
Dividends Paid1.67M7.60M11.40M11.34M11.46M7.60M3.55M1.22M488.12K111.38M204.20M185.63M92.82M1.12M1.16M111.47M
FCF to OCF-80.26%95.68%121.07%105.30%385.04%75.47%107.69%80.72%68.38%65.59%76.44%384.87%586.74%43.99%77.97%
Dividend Paid to FCF-28.44%11.19%-70.19%-30.83%-245.92%28.09%-2.25%0.12%30.47%53.64%42.78%-45.66%-0.72%0.64%21.94%

Earnings

Report DateJun 30, 2015Dec 19, 2015Feb 29, 2016Apr 27, 2016Aug 18, 2016Oct 20, 2016Dec 31, 2016Apr 20, 2017Aug 17, 2017Oct 19, 2017Dec 31, 2017Apr 26, 2018Aug 15, 2018Oct 30, 2018Dec 31, 2018Apr 29, 2019Aug 21, 2019Oct 24, 2019Dec 31, 2019Apr 30, 2020Aug 26, 2020Oct 26, 2020Dec 31, 2020Apr 28, 2021Aug 27, 2021Oct 28, 2021Dec 31, 2021Apr 30, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Apr 28, 2024Aug 29, 2024Sep 30, 2024Dec 31, 2024Apr 27, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------------------------
EPS Actual0.040.00-0.00-0.030.010.030.02-0.020.040.030.020.030.020.013.830.200.210.220.210.210.130.270.260.190.090.14-0.010.02-0.01-0.09-0.17-0.07-0.10-0.030.040.030.050.060.040.060.110.070.010.090.04
Surprise---------------------------------------------
Timing-After-hoursAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketAfter-hours-Pre-marketPre-marketAfter-hours-After-hoursPre-marketAfter-hours-Pre-market-------Pre-market-------Pre-marketPre-market--Pre-market-----

Key Statistics & Ratios

Market Cap12.58B
Enterprise Value9.71B
Trailing P/E64.52
Forward P/E0.00
Price / Sales7.66
Price / Book3.73
EPS0.21
Book Value3.47
Revenue (TTM)1.64B
Gross Profit (TTM)1.32B
EBITDA312.89M
Profit Margin12.01%
Operating Margin5.83%
Return on Equity6.12%
Return on Assets2.64%
Shares Outstanding928.16M
Shares Float264.66M
Beta0.08
Dividend Yield0.89%
Dividend Rate0.12
Payout Ratio56.47%

Dividends

20261×
0.12Jun 18, 2026
20251×
0.12Jun 16, 2025
20221×
0.10Jun 20, 2022
20211×
0.20Jun 18, 2021
20201×
0.22Jun 19, 2020
20191×
0.12Jun 27, 2019
20181×
0.25May 31, 2018
20171×
0.01Jun 29, 2017
20161×
0.02May 31, 2016
20151×
0.04Aug 12, 2015

Stock Splits

  • May 31, 20181.7:1